Attendee search 

Company Description

Napp is part of a privately owned global network of independent associated companies. In Europe, Mundipharma and Napp have sales revenues of over $1bn combined.

We are an asset led, highly entrepreneurial and commercially minded business that is focussed on providing innovative medicines to UK patients across all parts of the NHS. We are ambitious to be a leading partnership selling organisation; creating strong and effective partnerships with commercial partners, healthcare providers and patients.

Structured in Business Units around our four commercial platforms of Primary Care, Specialty Care, Biosimilars and Branded Generics, we are able to make fast decisions and focus on the right products in the right areas.

Qdem, our branded generics house is a wholly owned subsidiary of Napp. Qdem has a team of 8 dedicated KAMs who cover the whole of the UK. We have had great success in gaining and maintaining market share with our branded generics Butec®, Longtec® and Shortec®.

Our other leading brands at Napp include Invokana® for Type II diabetes, Flutiform® for asthma and Remsima®, Truxima® and Herzuma® (biosimilars of infliximab, rituximab and trastuzumab).

We offer

Napp has exceptionally capable marketing, sales and market access matrix teams, which effectively build and grow originator products in competitive indication areas, and enjoy an excellent reputation in the NHS and with GPs and UK KOLs. Mundipharma has both a heritage and reputation for excellence in pharmaceutical marketing and sales around the world, and an excellent reputation with healthcare practitioners throughout our region.

We have the support and remit to grow quickly our Qdem UK generics business through the in-licensing and acquisition of assets. Our Qdem marketing and sales team consists of originator salespeople from within and outside of the Napp Pharmaceuticals business with superb payer, formulary and healthcare practitioner contacts, and has excellent experience for the launch of both complex and value added branded generics in the UK.

We are interested in:

We are looking for dossiers and supply across all therapy areas (but particularly respiratory, urology, CNS & gastroenterology) for the following:

Value add generics, with novel dose forms or strengths

Generic drug delivery devices

Other complex delivery forms

Delayed or complex release forms across all therapy areas

Napp is keen to explore partnership opportunities for NCEs, biologics, biosimilars, orphan medicines and generics.

We are not interested in

Immediate release generics.

Hospital tender only generics.

API. CRO, CSO or CMO services.

Silence Therapeutics is a leading RNAi company, developing highly innovative medicines with life-saving potential for patients with serious and rare diseases, based upon its proprietary technology platform in GalNAc conjugated siRNA.

The Company is in a strong position to maximise the potential of its IP and technology through collaborations and the advancement of internal programmes toward the clinic. Silence’s lead candidate SLN124 will move into clinical development in the coming year.